• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » TAVI: Direct Flow’s LeMaitre touts real-world data for next-gen heart valve

TAVI: Direct Flow’s LeMaitre touts real-world data for next-gen heart valve

October 20, 2015 By Fink Densford

Direct Flow MedicalDirect Flow Medical said last week that 1-year data from a post-market study of its transcatheter aortic valve implantation system showed a 95% rate of mild or no paravalvular regurgitation.

The low rate of paravalvular leaks is of primary importance to the TAVI market, Direct Flow CEO Dan LeMaitre told MassDevice.com last week, as the procedures become more common and the technology moves from only extreme risk patients to those with surgical options.

“As we start to see this therapy adopted in broader portions of the population, we’re going to have to be less cavalier about paravalvular leaks because you can stress a heart for a long time with residual regurgitation,” LeMaitre said. “As you know, patients always want less invasive options. When you can marry a less invasive procedure with outcomes that are either on par, and some of the survivor data would suggest better than surgery, its pretty telling value proposition. So the fact that at 1 year we had 95% of our patients that had PVL of mild or less, thats a significant finding.”

LeMaitre joined Direct Flow last May from Medtronic (NYSE:MDT), where he landed after leading CoreValve to an $800 million acquisition by the medical giant.

The registry data, from a study of 200 patients treated with Direct Flow device, showed an 82% rate of freedom from all-cause mortality and a 90% freedom from cardiovascular mortality at 1 year. The numbers line up with those demonstrated during the company’s pivotal trial of the device, LeMaitre told us.

“When you do look at our rates of PVL, it is certainly some of the lowest rates of PVL in TAVI devices. We also had a freedom from all-cause mortality, or survival rate, of 82% at 1 year, which again is some of the best data out there in terms of extreme-risk patients,” he said. “And again, by definition, extreme-risk patients are deemed not candidates for surgery. So that’s the most exciting message. We’ve been able to show, in a real-world setting, in a post-market registry, that the results we had in our original pivotal study are confirmed with this 1 year data.”

LeMaitre said that the rate of new bradycardia pacemaker dependence also made Direct Flow’s device stand out from the crowd, reporting a 12% rate of dependance on newly placed brady pacers in patients treated with the device.

“Our rate of pacing in this study, new Brady pacemaker dependency, is 12%, which again is some of the lowest new patient pacing numbers that have been demonstrated. And we think our numbers are headed lower,” he said. “Some of the competitive devices we’re facing in the market have rates of 15% to 20%, and 1 of them is actually over 30%. So it’s a significant benefit because you simply don’t want to have patients become Brady pacemaker-dependent. There’s also obviously cost of having to put Brady pacemakers in patients.”

Lemaitre, at 1 time a healthcare analyst for Merrill Lynch and Cowen & Co., worked as Medtronic’s senior vice president for strategic planning & business development before moving to the CEO spot at CoreValve in 2008. Medtronic acquired CoreValve the next year. He is also chairman at Bioventus, a Smith & Nephew (FTSE:SN, NYSE:SNN) spinout, lead director at Endologix (NSDQ:ELGX) and a director at Globus Medical (NYSE:GMED).

Having spent more than 7 years in the TAVI market, LeMaitre said it’s satisfying to see how the industry is changing and the effects the transcatheter technology was making on the market.

“I think its incredibly gratifying as this market now comes on its 8th year, that there are now probably close to 80,000 patients or so patients that will receive a TAVI device this year. The market is somewhere between $1.5 billion to $2 billion. It’s a huge referendum on the utility of the tech,” LeMaitre said. “At the end of the day, it appears most clinicians who are treating patients will tell you that this will eventually be used not only in extreme-risk, but high- and intermediate-risk, and even talk about going into low-risk patients. So it’s gratifying to watch this technology change lives, save lives. I think it’s something that when you step back and look at seminal events in the medical device industry, there’s very few times when you can just look at a paradigm change and recognize that amazing things are being done for patients.”

Direct Flow’s system received CE Mark in January 2013. The company is enrolling subjects in a planned, 1,000-patient pivotal study of the device in the U.S., LeMaitre told us.

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Vascular Tagged With: Direct Flow Medical Inc.

In case you missed it

  • FDA clears VySpine’s VyPlate anterior cervical plate system
  • Technical Brief – “Understanding the Extensive OEM Benefits of Total Linear Motion Solutions.”
  • Exactech launches total hip arthroplasty system
  • Lensar announces first patients treated with Ally adaptive cataract treatment
  • HeartBeam submits heart attack diagnostic platform for FDA 510(k) clearance
  • GE Healthcare leads AliveCor Series F funding for ECG tech
  • New FDA ruling may lower costs for over-the-counter hearing aids
  • Data supports Sight Sciences’ Omni surgical system for glaucoma
  • Integra founder Richard Caruso has died
  • Moximed raises $40M for implantable shock absorber for knee osteoarthritis
  • Philips names Roy Jakobs as CEO amid ventilator, CPAP recalls
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy